Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 2
2005 1
2006 4
2007 6
2008 2
2009 2
2010 1
2011 1
2012 3
2013 2
2014 3
2016 4
2017 3
2018 5
2019 7
2020 13
2021 7
2022 9
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin.
Souleymane MB, Kadri S, Piubello A, Tsoumanis A, Soumana A, Issa H, Amoussa AK, Van Deun A, Lynen L, de Jong BC, Decroo T. Souleymane MB, et al. Among authors: van deun a. Int J Infect Dis. 2023 Aug;133:78-81. doi: 10.1016/j.ijid.2023.05.002. Epub 2023 May 5. Int J Infect Dis. 2023. PMID: 37150352 Free article. Clinical Trial.
Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation.
Souleymane MB, Decroo T, Soumana A, Maman Lawan I, Gagara-Issoufou A, Halidou-Moussa S, Ortuño-Gutiérrez N, Adehossi E, Mamadou S, Van Deun A, Piubello A. Souleymane MB, et al. Among authors: van deun a. Trials. 2022 Dec 13;23(1):1011. doi: 10.1186/s13063-022-06912-7. Trials. 2022. PMID: 36514153 Free PMC article.
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang CY, Conradie F, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Narendran G, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators. Goodall RL, et al. Among authors: van deun a. Lancet. 2022 Nov 26;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5. Epub 2022 Nov 8. Lancet. 2022. PMID: 36368336 Free PMC article. Clinical Trial.
Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
Souleymane MB, Decroo T, Mamadou S, Soumana A, Lawan IM, Gagara-Issoufou A, Adehossi E, Ortuño-Gutiérrez N, Lynen L, Rigouts L, de Jong BC, Van Deun A, Piubello A. Souleymane MB, et al. Among authors: van deun a. Int Health. 2023 May 2;15(3):258-264. doi: 10.1093/inthealth/ihac016. Int Health. 2023. PMID: 35420123 Free PMC article.
79 results